Moderately Hypofractionated Intensity Modulated Radiation Therapy with Simultaneous Integrated Boost for Prostate Cancer: Five-Year Toxicity Results from a Prospective Phase I/II Trial
| Autor: | A. Ricco, Drew Moghanaki, Michael G. Chang, Nitai D. Mukhopadhyay, Diane Holdford, Vicki Skinner, Mitchell S. Anscher, Siddharth Saraiya, Xiaoyan Deng |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty Urology lcsh:RC254-282 Androgen deprivation therapy 03 medical and health sciences Prostate cancer 0302 clinical medicine prostate radiation therapy Prostate Median follow-up medicine gastrointestinal toxicity Lymph node pelvic lymph nodes business.industry clinical trial moderate hypofractionation lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Clinical trial Regimen 030104 developmental biology medicine.anatomical_structure Oncology patient reported outcome measures simultaneous integrated boost 030220 oncology & carcinogenesis Toxicity genitourinary toxicity business |
| Zdroj: | Frontiers in Oncology, Vol 10 (2020) Frontiers in Oncology |
| Popis: | Background In this phase I/II trial, 5-year physician-assessed toxicity and patient reported quality of life data is reported for patients undergoing moderately hypofractionated intensity modulated radiation therapy (IMRT) for prostate cancer using a simultaneous integrated boost (SIB) and pelvic lymph node (LN) coverage. Materials and methods Patients with T1-T2 localized prostate cancer were prospectively enrolled, receiving risk group based coverage of prostate ± seminal vesicles (SVs) ± pelvic lymph nodes (LNs). Low risk (LR) received 69.6 Gy/29 fractions to the prostate, while intermediate risk (IR) and high risk (HR) patients received 72 Gy/30fx to the prostate and 54Gy/30fx to the SVs. If predicted risk of LN involvement >15%, 50.4 Gy/30fx was delivered to pelvic LNs. Androgen deprivation therapy was given to IR and HR patients. Results There were 55 patients enrolled and 49 patients evaluable at a median follow up of 60 months. Included were 11 (20%) LR, 23 (41.8%) IR, and 21 (38.2%) HR patients. Pelvic LN treatment was given in 25 patients (51%). Prevalence rates of late grade 2 GI toxicity at 1, 3, and 5 years was 5.8, 3.9, and 5.8%, respectively, with no permanent grade 3 events. Prevalence rates of late grade 2 GU toxicity at 1, 3, and 5 years rates were 15.4, 7.7, and 13.5%, respectively, with three grade 3 events (5.8%). The biochemical relapse free survival at 5 years was 88.3%. There were no local, regional, or distant failures, with all patients still alive at last follow up. Conclusion Moderate hypofractionation of localized prostate cancer utilizing a SIB technique and LN coverage produces tolerable acute/late toxicity. Given equivalent efficacy between moderate hypofractionation schedules, the optimal regimen will be determined by long-term toxicity reported from both the physician and patient perspective. Clinical trial registration www.ClinicalTrials.gov, identifier NCT01117935, Date of Registration: 5/6/2010. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|